ArticleBMC infectious diseases2025
Using linked national registry data and the ECDC HIV modelling tool to estimate HIV incidence and the proportion diagnosed in Norway up to 2023.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Late HIV diagnosis: trends, risk factors, and progress toward the 2025 target of <20% late diagnosis in 23 EU/EEA countries, 2022 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEstimates of HIV incidence and the size of the undiagnosed population are important to monitor epidemic trends, assess progress towards regional and global goals, and inform ongoing prevention and control measures. Previous estimates from Norway date back to 2018 and did not account for pre-migration infection among migrants. This is essential when modelling the HIV epidemic in countries like Norway, where over 80% of new HIV diagnoses are among migrants who reportedly acquired HIV before migration.
methodI estimated the incidence of new HIV infections, number undiagnosed and proportion diagnosed overall and in key groups at risk of HIV acquisition up until the end of 2023 in Norway. I used linked national registry data and the ECDC HIV modelling tool, a back-calculation compartmental model that uses routine surveillance data on HIV diagnoses. The modelling tool estimates pre-migration infections by comparing the known date of migration to the estimated date of infection. I generated estimates overall and for four subgroups: Norwegian-born men who have sex with men (MSM), Norwegian-born heterosexual transmission, migrant MSM and migrant heterosexual transmission.
resultsThe model input data included 7,185 new HIV diagnoses up to the end of 2023, of which 4,266 (59%) were migrants. The model estimated that 86% (95% confidence interval (CI): 83% – 88%) of new infections among migrants were pre-migration infections. Excluding these, there were 13 (95% CI: 11 – 50) new HIV infections in Norway in 2023. There were 234 (95% CI: 207 – 336) undiagnosed PLHIV and the proportion diagnosed was 96.5% (95% CI: 95.1% – 96.9%). The diagnosed fraction was under 95% among Norwegian-born heterosexual transmission (92.6%; 95% CI: 87.1% – 94.5%) and migrant MSM (92.2%; 95% CI: 90.8% – 93.8%).
conclusionsOverall, Norway has achieved the global target of diagnosing 95% of people living with HIV. The incidence of new HIV infections is low. Existing measures should be maintained and strengthened to further reduce the undiagnosed population and prevent transmission. The lower proportion diagnosed among Norwegian-born persons infected through heterosexual transmission and migrant MSM indicates where larger relative improvements may be made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.